Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.
Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, Gleisner S, Schulze B, Goldinger SM, Berking C, Forschner A, Clemens P, Grabenbauer G, Müller-Brenne T, Bauch J, Eich HT, Grabbe S, Schadendorf D, Schuler G, Keikavoussi P, Semrau S, Fietkau R, Distel LV, Heinzerling L. Hecht M, et al. Among authors: forschner a. Ann Oncol. 2015 Jun;26(6):1238-1244. doi: 10.1093/annonc/mdv139. Epub 2015 Mar 11. Ann Oncol. 2015. PMID: 25762352 Free article.
Whole-Body Magnetic Resonance Imaging (MRI) for Staging Melanoma Patients in Direct Comparison to Computed Tomography (CT): Results from a Prospective Positron Emission Tomography (PET)/CT and PET/MRI Study.
Reinert CP, Liang C, Weissinger M, Vogel J, Forschner A, Nikolaou K, la Fougère C, Seith F. Reinert CP, et al. Among authors: forschner a. Diagnostics (Basel). 2023 Jun 5;13(11):1963. doi: 10.3390/diagnostics13111963. Diagnostics (Basel). 2023. PMID: 37296815 Free PMC article.
In vivo imaging of CD8+ T cells in metastatic cancer patients: first clinical experience with simultaneous [89Zr]Zr-Df-IAB22M2C PET/MRI.
Schwenck J, Sonanini D, Seyfried D, Ehrlichmann W, Kienzle G, Reischl G, Krezer P, Wilson I, Korn R, Gonzalez-Menendez I, Quintanilla-Martinez L, Seith F, Forschner A, Eigentler T, Zender L, Röcken M, Pichler BJ, Flatz L, Kneilling M, la Fougere C. Schwenck J, et al. Among authors: forschner a. Theranostics. 2023 Apr 17;13(8):2408-2423. doi: 10.7150/thno.79976. eCollection 2023. Theranostics. 2023. PMID: 37215571 Free PMC article.
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T, Sinnberg T, Chatziioannou E, Niessner H, Leiter U, Keim U, Forschner A, Dwarkasing J, Tjien-Fooh F, Wever R, Flatz L, Eggermont A, Forchhammer S. Amaral T, et al. Among authors: forschner a. Eur J Cancer. 2023 Mar;182:155-162. doi: 10.1016/j.ejca.2022.12.021. Epub 2022 Dec 30. Eur J Cancer. 2023. PMID: 36739215 Free article.
UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescents.
Liebmann A, Admard J, Armeanu-Ebinger S, Wild H, Abele M, Gschwind A, Seibel-Kelemen O, Seitz C, Bonzheim I, Riess O, Demidov G, Sturm M, Schadeck M, Pogoda M, Bien E, Krawczyk M, Jüttner E, Mentzel T, Cesen M, Pfaff E, Kunc M, Forchhammer S, Forschner A, Leiter-Stöppke U, Eigentler TK, Schneider DT, Schroeder C, Ossowski S, Brecht IB. Liebmann A, et al. Among authors: forschner a. EBioMedicine. 2023 Oct;96:104797. doi: 10.1016/j.ebiom.2023.104797. Epub 2023 Sep 14. EBioMedicine. 2023. PMID: 37716236 Free PMC article.
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system.
Renovanz M, Kurz SC, Rieger J, Walter B, Becker H, Hille H, Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk DJ, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C, Brucker SY, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö, Beha J, Malek HS, Möller Y, Ruhm K, Tatagiba M, Schittenhelm J, Bitzer M, Malek N, Zips D, Tabatabai G. Renovanz M, et al. Among authors: forschner a. Neurooncol Adv. 2023 Feb 14;5(1):vdad012. doi: 10.1093/noajnl/vdad012. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 36915613 Free PMC article.
Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study.
L'Orphelin JM, Cassecuel J, Kandolf L, Harwood CA, Tookey P, Junejo MH, Hogan S, Lebbé C, Appalla Z, Kränke TM, Pellacani G, Cerasuolo D, Dujovic B, Del Marmol V, Forschner A, Garbe C, Bataille V, Ressler JM, Sollena P, Dompmartin A, Peris K, Dreno B; And European Association of Dermato-Oncology. L'Orphelin JM, et al. Among authors: forschner a. J Eur Acad Dermatol Venereol. 2023 Apr 12. doi: 10.1111/jdv.19112. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 37042810
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, Roesch A, Weide B, Eigentler T, Schadendorf D, Garbe C, Kulms D, Quintanilla-Martinez L, Meier F. Niessner H, et al. Among authors: forschner a. Cancer Med. 2013 Feb;2(1):76-85. doi: 10.1002/cam4.50. Epub 2013 Feb 3. Cancer Med. 2013. PMID: 24133630 Free PMC article.
140 results